CGT Catapult Forms Consortium to Accelerate Manufacturing Technology Development

BioPharm International Editors

The CGT Catapult has formed a consortium aimed at advancing the technology development and lowering costs of cell and gene therapy manufacturing.

The Cell and Gene Therapy Catapult (CGT Catapult) has formed a consortium of more than 20 organizations aimed at advancing the technology development and lowering costs of cell and gene therapy manufacturing.

In a June 8, 2021 press release, CGT Catapult announced the formation of the consortium, which will assess multiple process analytical technologies (PAT) that are either new or routinely used in other industries. Through collaboration and sharing of information, the consortium will act as a catalyst to accelerate the development of the necessary knowledge and understanding at reduced cost and investment risk to each organization.

“The industry needs to make a giant leap in terms of analytical capability and the dynamic use of information to control and improve processes, product, and costs,” said Matthew Durdy, CEO at CGT Catapult, in the press release. “The coming together of these leaders in the field is a very important first step towards achieving this.”

“By sharing knowledge and data, the consortium members will be able to reap potentially huge benefits that could lead to more efficient processes in this vital field,” added Nicholas Medcalf, deputy challenge director—Medicines Manufacturing for Innovate UK, in the press release. “The Cell and Gene Therapy Catapult—supported by Innovate UK—is demonstrating its fantastic convening power in harnessing these leading industry players for the greater good of UK enterprise and innovation.”

Source: CGT Catapult